When was NetraMark founded?

NetraMark was founded in 2015 and raised its 1st funding round 2 years after it was founded.

Where is NetraMark located?

NetraMark is headquartered in Toronto, Canada.

How many employees does NetraMark have?

As of Aug 31, 2026, the latest employee count at NetraMark is 30.

Is NetraMark a funded company?

NetraMark is a funded company, having raised an undisclosed amount across 6 funding rounds to date. The company's 1st funding round was a $***** Grant (prize money) round, raised on Jun 21, 2017.

When was the latest funding round of NetraMark?

NetraMark's latest funding was a $***** Post IPO round on Jan 13, 2026, with participation from 0 investor.

Where does NetraMark rank among its competitors?

NetraMark ranks 24th amongst 299 active competitors, of which 50 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Verily, which secured an undisclosed amount in Sep, 2026.

Who are the top competitors of NetraMark?

NetraMark's top competitors include Medidata, Verily and IQVIA. Among them, Verily secured the most recent funding round in September, 2026.

NetraMark - 2026 Company Profile, Team, Funding & Competitors

Company Details

NetraMark provides an AI-assisted platform for drug discovery and development. The platform utilizes machine learning technology for the prediction of the lead candidates. The company claims to provide ALS predictions, responses to anti-depressant drugs, and predict placebo responses.

Website: www.netramark.com/
Social
Email ID: *****@netramark.com
Phone Number: +1 **********

Key Metrics

Founded Year

2015

Location

Toronto, Canada

Stage

Public

Latest Funding Round

Post IPO, Jan 13, 2026, $*****

Investors

JLABS & 2 more

Ranked

24^th among 299 active competitors

Employee Count

30 as on Aug 31, 2026

Similar Companies

Medidata & 341 more

Exit Details

Public

View NetraMark's full profile

NetraMark got listed on Jun 07, 2021.

Click here to take a look at NetraMark's IPO in detail

NetraMark has raised funding over 6 rounds. Its first funding round was on Jun 21, 2017. NetraMark has 3 institutional investors.

Here is the list of recent funding rounds of NetraMark:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jan 13, 2026	1088796	Post IPO	5260544	5072033	8730786	1395611
Dec 16, 2025	3870043	Grant (prize money)	1085847	8434071	8382859	4420926
Sep 19, 2023	9030236	Post IPO	4457334	7551016	3366806	2942090

Access funding benchmarks and valuations. Sign up today!

View details of NetraMark's funding rounds and investors

The founders of NetraMark is Richard Brooks,.

Here are the details of NetraMark's key team members:

Richard Brooks,: Co-Founder & COO of NetraMark.

View details of NetraMark's Founder profiles and Board Members

NetraMark's employee count trend

NetraMark has 30 employees as of Aug 26. Here is NetraMark's employee count trend over the years:

Uncover NetraMark's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of NetraMark include Medidata, Verily and IQVIA. Here is the list of Top 10 competitors of NetraMark, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Medidata 1999, New York City (United States), Acquired	AI-based clinical trial management software for researchers	$41.5M	Insight Partners, TFS & 11 others	86/100
2nd	Verily 2015, Dallas (United States), Series D	A data platform and technology company purpose-built to power AI-enabled precision health	$2.8B	Silver Lake, Temasek & 11 others	82/100
3rd	IQVIA 1982, Durham (United States), Public	Provider of clinical research and commercialization solutions for healthcare	$1.74M	Leonard Green and Partners, Aisling Capital ... & 12 others	80/100
4th	Tempus 2015, Chicago (United States), Public	Developer of genomic testing and artificial intelligence tools for medicine	$1.05B	T. Rowe Price, New Enterprise Associates ... & 11 others	77/100
5th	Signant Health 2000, Plymouth Meeting (United States), Acquired	Provider of a software solution for clinical trial management	$3.4M	Harvest Partners, 3i Group & 4 others	72/100
6th	Science 37 2014, Los Angeles (United States), Acquired	Provider of a suite solution for clinical trials for researchers	$106M	Redmile Group, Lux Capital & 12 others	70/100
7th	TriNetX 2013, Cambridge (United States), Acquired	Provider of clinical trial management software for researchers and professionals	$102M	Merck Global Health Innovation Fund, F2 Ventures ... & 6 others	66/100
8th	Wcg Clinical 2012, Princeton (United States), Acquired	CRO offering regulatory and ethical review services for clinical research	-	Ares Capital Corporation, Prospect Capital ... & 6 others	64/100
9th	Obvio Health 2015, Orlando (United States), Series B	Provider of clinical trials design and recruitment platform	$66M	Dedalus Group, Guardant Health & 13 others	62/100
10th	ProofPilot 2012, New York City (United States), Series D	Platform for the development & execution of research studies	$28.1M	Mitsui, Cue Ball & 8 others	60/100
24th	NetraMark 2015, Toronto (Canada), Public	AI-assisted platform for drug discovery and development	-	JLABS, Ontario Brain Institute & 1 others	53/100